Elevated Tumor Cell-Intrinsic STING Expression in Advanced Laryngeal Cancer.
Ontology highlight
ABSTRACT: Laryngeal cancer is the second most common malignancy of the head and neck, worldwide. Immunotherapy targeting checkpoint inhibitors has been approved for the treatment of patients with recurrent or metastatic laryngeal cancer but has a relatively low response rate and outcomes that leave many patients underserved. Targeting the cGAS-STING signaling pathway can potentially improve the activation of immune effector cells, although its role in the development and progression of laryngeal cancer has not yet been investigated in depth. Fifty-nine tumor samples from patients with pathologically confirmed squamous cell carcinoma of the larynx, stage I-IV non-metastatic disease, who were treated at the University Hospital of Split, were immunohistochemically stained for the expression of STING, c
SUBMITTER: Viculin J
PROVIDER: S-EPMC10341367 | biostudies-literature | 2023 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA